Design preview. These 10 sample stories are real, recent news written to test the layout. The site stays out of search until launch.
biohack.The longevity wire
LIVE WIREUpdated · scanning every 6 hours
18:00 Veradermics’ oral minoxidil pill VDPHL01 meets Phase 3 goals in 536 men✦14:00 FDA approves bepirovirsen, a finite treatment for chronic hepatitis B✦15:00 Dave Asprey's first psychedelics conference draws about 600 to Austin✦14:00 Life Biosciences reports first human data for ER-100 reprogramming therapy✦14:00 Novo and Lilly report lower aging-clock readings on GLP-1 drugs✦14:00 High-dose NMN raised NAD+ in older adults but did not improve hearing✦14:00 Loyal's large-dog pill LOY-003 clears an FDA efficacy review step✦14:00 AI-designed drug rentosertib lowers aging-clock scores in small IPF trial✦18:00 Veradermics’ oral minoxidil pill VDPHL01 meets Phase 3 goals in 536 men✦14:00 FDA approves bepirovirsen, a finite treatment for chronic hepatitis B✦15:00 Dave Asprey's first psychedelics conference draws about 600 to Austin✦14:00 Life Biosciences reports first human data for ER-100 reprogramming therapy✦14:00 Novo and Lilly report lower aging-clock readings on GLP-1 drugs✦14:00 High-dose NMN raised NAD+ in older adults but did not improve hearing✦14:00 Loyal's large-dog pill LOY-003 clears an FDA efficacy review step✦14:00 AI-designed drug rentosertib lowers aging-clock scores in small IPF trial
← All story threadsSTORY THREAD

Bepirovirsen for chronic hepatitis B.

1 report so far. New developments are added to this thread as they happen.

  1. Oct 20, 2026
    FDA APPROVAL AS HIBSAGOFDA approval · Phase 3

    FDA approves bepirovirsen, a finite treatment for chronic hepatitis B

    Hibsago, GSK's antisense drug, is given for a fixed 24 weeks with the aim of a functional cure. In phase 3 trials, about one in five eligible patients reached that goal.